From: Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients
A) | ||||
---|---|---|---|---|
SARS-CoV-2 | NCAP | 157IVLQLPQGTTLPKGFYAEG175 | 221LLLLDRLNQLESKMS235 | 393TLLPAADLDDFSKQL407 |
SARS-CoV | NCAP | 157ATVLQLPQGTTLPKGYAEG175 | 221ALLLLDRLNQLESKV235 | 393VTLLPAADMDDFSRQ407 |
SARS-CoV-2 | SPIKE | 1145LDSFKEELDKYFKNH1159 | ||
SARS-CoV | SPIKE | 1129SFKEELDKYFKNHTS1143 | ||
MERS | SPIKE | 1225NSTGIDFQDELDEFF1243 |
B) | ||||
---|---|---|---|---|
SARS-CoV-2 | NCAP | 109YFYYLGTGPEAGLPY123 | ||
SARS-CoV | NCAP | 101KMKELSPRWYFYYLG115 | ||
OC43 | NCAP | 113DGNQRQLLPRWYFYY127 121PRWYFYYLGTGPHAK135 | ||
MERS | NCAP | 89NGIKQLAPRWYFYYT103 93QLAPRWYFYYTGTGP107 | ||
NL63 | NCAP | 77HFYYLGTGPHKDLKF91 | ||
SARS-CoV-2 | SPIKE | 553TESNKKFLPFQQFGR567 | 1201QELGKYEQYIKWPWY1215 | |
SARS-CoV | SPIKE | 537VLTPSSKRFQPFQQF551 | ||
OC43 | SPIKE | 1285KDIGTYEYYVKWPWY1299 | ||
NL63 | SPIKE | 1285LLNRFENYIKWPWWV1299 | ||
229E | 1105LNRVETYIKWPWWVW1119 |